Regenxbio (RGNX) Shares Outstanding (Diluted Average) (2016 - 2025)
Regenxbio (RGNX) recorded quarterly Shares Outstanding (Diluted Average) of $51.6 million in Q4 2025, little changed quarter-over-quarter from $51.7 million in Q3 2025, and up 4.17% on a YoY basis from $49.5 million in Q4 2024.
Regenxbio (RGNX) Shares Outstanding (Diluted Average) (2016 - 2025) Analysis & Trends
Regenxbio's Shares Outstanding (Diluted Average) history runs 10 years deep, the most recent figure standing at $51.6 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 4.17% year-over-year to $51.6 million; the TTM figure through Dec 2025 stood at $51.6 million (up 4.17% YoY), while the FY2025 annual figure was $51.6 million, up 4.17% from the prior year.
- Shares Outstanding (Diluted Average) was $51.6 million for Q4 2025 at Regenxbio, roughly flat from $51.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $51.7 million in Q3 2025 to a low of $42510.0 in Q2 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $34.8 million across 5 years, with a median of $43.9 million in 2021.
- The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Diluted Average) sank 99.89% in 2021, then soared 101853.46% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $43.9 million in 2021, then slipped by 1.73% to $43.2 million in 2022, then gained by 1.35% to $43.7 million in 2023, then increased by 13.2% to $49.5 million in 2024, then rose by 4.17% to $51.6 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $51.6 million (Q4 2025), $51.7 million (Q3 2025), and $51.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 92.44 Mn |
| 10 | Regenxbio | 315.11 Mn | 85.04 Mn | - | 51.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.57 Mn |
| Sep 30, 2025 | 51.69 Mn |
| Jun 30, 2025 | 51.48 Mn |
| Mar 31, 2025 | 51.43 Mn |
| Dec 31, 2024 | 49.51 Mn |
| Sep 30, 2024 | 49.05 Mn |
| Jun 30, 2024 | 48.17 Mn |
| Mar 31, 2024 | 45.73 Mn |
| Dec 31, 2023 | 43.73 Mn |
| Sep 30, 2023 | 43.95 Mn |
| Jun 30, 2023 | 43.53 Mn |
| Mar 31, 2023 | 43.45 Mn |
| Dec 31, 2022 | 43.15 Mn |
| Sep 30, 2022 | 43,103.00 |
| Jun 30, 2022 | 43,028.00 |
| Mar 31, 2022 | 42,944.00 |
| Dec 31, 2021 | 43.91 Mn |
| Sep 30, 2021 | 42,629.00 |
| Jun 30, 2021 | 42,510.00 |
| Dec 31, 2020 | 37.28 Mn |